1 / 5

Filling Gaps during Carbon Footprint studies to design Green Pharmaceuticals

Filling Gaps during Carbon Footprint studies to design Green Pharmaceuticals. November, 2013. The Challenge . Initiatives such as the Swedish Voluntary Incentive Scheme are focusing on eco-footprint/LCA of pharmaceuticals

acacia
Download Presentation

Filling Gaps during Carbon Footprint studies to design Green Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Filling Gaps during Carbon Footprint studies to design Green Pharmaceuticals November, 2013

  2. The Challenge • Initiatives such as the Swedish Voluntary Incentive Scheme are focusing on eco-footprint/LCA of pharmaceuticals • Data availability is a significant issue when estimating material carbon footprint or Life Cycle Assessments (LCA) • Life Cycle Assessment research has repeatedly demonstrated that in API production, solvents play the biggest role. • Pharmaceutical companies can access data for solvent and other materials by taking out a license to EcoInvent or similar database, but data gaps on research materials tend to be big.

  3. How this challenge has been overcome before? • In the early 2000s GlaxoSmithKine (GSK) developed a streamlined Life Cycle Assessment Tool (Fast Lifecycle Assessment of Synthetic Chemistry – or FLASCTM). • FLASCTM delivers footprint estimations in minutes by using the available footprint data of the materials used in a synthesis. When data is not available, FLASCTM fills the gaps using ‘average’ footprint estimations for a particular type of chemical. • These ‘average’ footprint numbers were derived using a statistical methodology, and have proven to render acceptable levels or uncertainty for more than a decade within GSK. • A description to FLASCTM is available in IJLCA 12(4) 272-280 (2007)

  4. How can the Roundtable help ? • The ACS GCI Pharmaceutical Roundtable developed a PMI/LCA tool for estimation of Process Mass Intensity and Life Cycle Assessment • The LCA estimation is based on the methodology published by GSK. • The PMI/LCA tool is described in OPRD, 17(2), 239-246 (2013) • GlaxoSmithKline approved the release of ‘average’ Global Warming Potential (GWP, carbon footprint) data so data gaps can be filled. • The roundtable companies agreed to use the PMI/LCA tool to benchmark their footprint. • Companies outside the ACS GCI Pharmaceutical Roundtable can use the ‘average’ footprint numbers in combination with data from other sources (e.g., EcoInvent, proprietary data, literature) to estimate the footprint

  5. “Average” Global Warming Potential (GWP) per chemical type • These figures represent a broad range to chemicals and are only applicable to fill data gaps that will • help to provide a high-level reasonable estimation of carbon footprint of Active Pharmaceutical Ingredients • when solvent data is known. These figures most likely will not translate outside the API production. • For further explanation of categories, go to IJLCA 12(4) 272-280 (2007). • For further explanation on how these numbers can be used go to OPRD, 17(2), 239-246 (2013). • Acknowledgement – GlaxoSmithKline for providing the GWP information.

More Related